Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Endocrinol Invest ; 38(4): 389-97, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25319469

RESUMO

PURPOSE: Several clinical studies testify the critical role played by estrogens in male bone metabolism. The aim of our study is to assess the effect of a single injection of testosterone enanthate in a group of hypogonadal men on 17ß estradiol serum levels and some bone metabolic parameters. METHOD: Twenty-one hypogonadal males were given one testosterone enanthate injection (250 mg). Blood samples were drawn before the injection and after 1, 2 and 3 weeks. The following variables were measured: Total testosterone (TT), 17ß estradiol (17ß E2), Sex hormone binding globulin, total alkaline phosphatase, osteocalcin, and C-telopeptide of type I collagen (CTx). RESULTS: After testosterone injection, both TT and 17ß E2 increased, peaking 1 week after the injection. Individual observation of the response of 17ß E2 to testosterone showed that a subgroup (n = 9) failed to respond with any increase in 17ß E2 at any of the weekly tests (group E2-), while the remainder (n = 12) showed a significant increase in 17ß E2, which reached a mean value three times higher than at baseline (group E2+). The E2- patients reached a TT peak lower than that observed in the E+ group. CTx serum levels declined progressively in the E2+ group, reaching the significance (p = 0.03) at the end of the study, while it did not change in E- group. CONCLUSION: This study suggests that a single injection of testosterone might have different effects on the production of endogenous estrogens, and a significant reduction of bone resorption parameters takes place only in the patients who show a significant increase of 17ß estradiol in response to testosterone administration.


Assuntos
Androgênios/farmacologia , Remodelação Óssea/efeitos dos fármacos , Estradiol/sangue , Hipogonadismo/tratamento farmacológico , Testosterona/análogos & derivados , Testosterona/sangue , Adulto , Androgênios/administração & dosagem , Biomarcadores/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Testosterona/administração & dosagem , Testosterona/farmacologia
2.
Pituitary ; 16(2): 175-81, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22585010

RESUMO

A high incidence of venous thromboembolic (VTE) complications has been reported in Cushing's syndrome (CS), mostly post-operatively and attributable to hypercoagulability. The prevalence of symptomatic VTE was investigated retrospectively in 58 consecutive CS patients in relation to acquired and genetic thrombotic risk factors. Eight CS patients (14 %) developed VTE (group A), 3 of them related and 5 unrelated to surgery. These patients had higher urinary free cortisol (p = 0.01) and VWF levels (p = 0.02) than the 50 patients without VTE (group B), as well an increase in the hemostatically more efficient, high-molecular-weight VWF multimers (p = 0.002). Factor V Leiden and the prothrombin gene 20210A variants (the most common inherited thrombophilic defects) were more represented in group A than in group B, as was the genotype GCAG/GCAG of the VWF gene promoter, known to hyperinduce VWF upregulation under cortisol excess. All but one of the patients with VTE unrelated to surgery had at least four acquired and at least one inherited risk factor. Severe hypercortisolism and VWF levels with increased haemostatic activity are strongly associated with VTE in CS. VTE episodes unrelated to surgery are attributable to the synergistic action of acquired and inherited thrombotic risk factors. Based on these observations, we believe that severely affected CS patients should be screened for coagulation disorders and receive antithrombotic prophylaxis whenever they have concomitant prothrombotic risk factors.


Assuntos
Síndrome de Cushing/complicações , Tromboembolia Venosa/diagnóstico , Tromboembolia Venosa/etiologia , Adulto , Síndrome de Cushing/genética , Síndrome de Cushing/metabolismo , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Tromboembolia Venosa/genética , Tromboembolia Venosa/metabolismo
3.
J Neuroendocrinol ; 23(7): 641-9, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21554434

RESUMO

Somatic mutations in the GNAS1 gene, encoding the α-subunit of the heterotrimeric stimulatory G protein (Gαs), occur in approximately 40% of growth hormone (GH)-secreting pituitary tumours. By altering the adenylate cyclase-cAMP-protein kinase A pathway, they unequivocally give somatotroph cells a growth advantage. Hence, the pathogenesis of somatotropinomas could be linked to anomalies in receptors coupled to the cAMP second-messenger cascade. Among them, the glucose-dependent insulinotropic polypeptide receptor (GIPR) is already known to play a primary role in the impaired cAMP-dependent cortisol secretion in patients affected by food-dependent Cushing's syndrome. In the present study, 43 somatotropinomas and 12 normal pituitary glands were investigated for GIPR expression by quantitative reverse transcriptase-polymerase chain reaction, western blotting and immunohistochemistry. Tumoural specimens were also evaluated for GNAS1 mutational status. The effect of GIPR overexpression on cAMP levels and GH transcription was evaluated in an in vitro model of somatotropinomas, the GH-secreting pituitary cell line GH3. GIPR was expressed at higher levels compared to normal pituitaries in 13 GNAS1 mutation-negative somatotropinomas. GIP stimulated adenylyl cyclase and GH-promoter activity in GIPR-transfected GH3 cells, confirming a correct coupling of GIPR to Gαs. In a proportion of acromegalic patients, GIPR overexpression appeared to be associated with a paradoxical increase in GH after an oral glucose tolerance test. Whether GIPR overexpression in acromegalic patients may be associated with this paradoxical response or more generally involved in the pathogenesis of acromegaly, as suggested by the mutually exclusive high GIPR levels and GNAS1 mutations, remains an open question.


Assuntos
Adenoma/genética , Subunidades alfa Gs de Proteínas de Ligação ao GTP/genética , Adenoma Hipofisário Secretor de Hormônio do Crescimento/genética , Hormônio do Crescimento Humano/genética , Regiões Promotoras Genéticas/fisiologia , Receptores dos Hormônios Gastrointestinais/genética , Somatotrofos/metabolismo , Acromegalia/complicações , Acromegalia/genética , Acromegalia/metabolismo , Adenoma/complicações , Adenoma/metabolismo , Adenoma/patologia , Adulto , Animais , Células Cultivadas , Cromograninas , Análise Mutacional de DNA , Feminino , Regulação Neoplásica da Expressão Gênica , Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações , Adenoma Hipofisário Secretor de Hormônio do Crescimento/metabolismo , Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia , Hormônio do Crescimento Humano/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Mutação/fisiologia , Ratos , Receptores dos Hormônios Gastrointestinais/metabolismo , Regulação para Cima/genética
4.
J Endocrinol Invest ; 34(5): 353-60, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20595802

RESUMO

BACKGROUND: Adrenal lesions are discovered in acromegaly more frequently than in general population, without relationship with primary disease. Some patients, carriers of aryl hydrocarbon receptor interacting protein (AIP) gene mutations, developed an adrenal neoplasm. AIM: To evaluate the role of metabolic and genetic aspects and the follow-up of adrenal nodules in acromegaly. MATERIAL AND METHODS: We studied 69 acromegalic patients (30 male and 39 female, 56 ± 15 yr) who had been referred to the Endocrinology Unit of Padua. In all patients we determined body mass index (BMI) and waist-to-hip ratio (WHR); we performed an oral glucose tolerance test (OGTT) whenever possible. If adrenal computed tomography revealed a lesion, the patient underwent an endocrine and genetic study. RESULTS: Adrenal lesions were identified in 14 patients and were not related to gender, duration of disease, GH or IGF-I concentrations, basal and after-OGTT glucose and insulin levels, log(HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) values, whereas BMI and WHR were higher in patients with adrenal lesions. Baseline endocrine and radiological study revealed benign lesions; during mean 4-yr follow-up none of the patients showed hormone excess, even though some lesions increased in size. We did not find any mutation in AIP gene, except heterozygous silent alteration (T48T). CONCLUSIONS: The frequency of non-functioning adrenal lesions in acromegaly is not associated with the considered aspects, except BMI and WHR. The prolonged follow-up showed that these lesions have a tendency to increase in size independently of the control of acromegaly, so a morphological follow- up is recommended.


Assuntos
Acromegalia , Glândulas Suprarrenais/metabolismo , Glândulas Suprarrenais/patologia , Peptídeos e Proteínas de Sinalização Intracelular/genética , Acromegalia/genética , Acromegalia/metabolismo , Acromegalia/patologia , Neoplasias das Glândulas Suprarrenais/genética , Neoplasias das Glândulas Suprarrenais/metabolismo , Neoplasias das Glândulas Suprarrenais/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Índice de Massa Corporal , Feminino , Seguimentos , Teste de Tolerância a Glucose , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Relação Cintura-Quadril , Adulto Jovem
5.
J Endocrinol Invest ; 34(8): e204-9, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21088471

RESUMO

UNLABELLED: Adrenal glands in Cushing's disease (CD) range from normal to showing diffuse enlargement in most cases. The finding of nodular lesions has been reported, but information about prevalence and evolution is described in few reports. AIM: To investigate the prevalence of nodular adrenal glands in patients with CD and assess its evolution after disease remission. SUBJECTS AND METHODS: We assessed 41 CD patients' abdominal computed tomography (CT) scans obtained during the active phase of the disease and evaluated the dynamics of ACTH and cortisol secretion. CT was repeated after disease remission in patients with adrenal nodules. RESULTS: Fifteen of 41 patients had nodular and the remaining 26 had normal or enlarged adrenal glands. Patients with nodules were older (45.1 ± 8.8 vs 36.9 ± 12.7 yr; p=0.03) and had longer-standing disease (57.3 ± 56.9 vs 32.9 ± 29.1 months; p=0.05) than patients with normal/enlarged adrenal glands. ACTH (45.4 ± 21.3 vs 70.5 ± 39.1 pg/ml; p=0.04) and urinary free cortisol levels (606.1 ± 512.3 vs 301.0 ± 224.7 µg/day, p=0.01) were significantly lower in patients with adrenal nodules while there were no differences between the groups in terms of dynamic tests results. Post-operative follow-up showed regression or shrinkage of the nodules in 8 out of 10 patients in disease remission. CONCLUSIONS: We found that adrenal nodular glands are a frequent finding in CD in particular in older patients and in those with a longerstanding disease. Nevertheless, a high percentage of nodules regression or shrinking was evidenced in our series after disease remission.


Assuntos
Glândulas Suprarrenais/patologia , Hipersecreção Hipofisária de ACTH/patologia , Adolescente , Hormônio Adrenocorticotrópico/metabolismo , Adulto , Seguimentos , Humanos , Hidrocortisona/metabolismo , Pessoa de Meia-Idade , Hipersecreção Hipofisária de ACTH/fisiopatologia , Hipersecreção Hipofisária de ACTH/cirurgia , Indução de Remissão , Estudos Retrospectivos , Tomografia Computadorizada por Raios X , Adulto Jovem
6.
J Endocrinol Invest ; 33(11): 800-5, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20354355

RESUMO

BACKGROUND: Mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene have been described in about 15% of kindreds with familial isolated pituitary adenomas and in a minority of early onset sporadic pituitary adenomas (PA). Among the AIP mutations reported so far, the R304X (AIPR304X) represents, together with the "Finnish mutation" Q14X, the most common one. METHODS: Three AIPR304X Italian families, including a newly reported kindred, have been genotyped for 12 genetic markers surrounding the AIP gene in order to look for a potential founder effect in Italy. Disease penetrance and genotype-phenotype correlations were also addressed. RESULTS: Analysis of chromosome 11' genetic markers revealed a common haplotype in 2 AIPR304X kindreds originating from central Italy. Overall, 17 mutations carriers were identified, including 7 patients and 10 unaffected subjects, respectively, arguing in this case for a disease penetrance of 41%. Mean age at diagnosis was 19.1±6.7 yr old, with females tending to be older than males. Though most PA were somatotropinomas (6/7), a great variability in disease severity was observed, even between subjects sharing the same at-risk haplotype. CONCLUSION: These data provide strong evidence for a new founder effect of the AIPR304X mutation in central Italy and the observed variations in disease severity point out the role of additional genetic or environmental factors in such kindreds.


Assuntos
Adenoma/genética , Peptídeos e Proteínas de Sinalização Intracelular/genética , Neoplasias Hipofisárias/genética , Adolescente , Adulto , Cromossomos Humanos Par 11/genética , Feminino , Efeito Fundador , Humanos , Perda de Heterozigosidade , Masculino , Mutação , Linhagem
7.
Blood Coagul Fibrinolysis ; 10(3): 145-51, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10357009

RESUMO

Glucocorticoids are known to increase plasma concentrations of factor VIII (FVIII) and von Willebrand factor (vWF), and their administration is associated with an increased incidence of thrombotic complications. Because Cushing's syndrome is characterized by an endogenous increase in glucocorticoids, we studied levels of FVIII and vWF in 20 patients with Cushing's syndrome. Plasma levels of FVIII and vWF were found to be markedly increased. Moreover, the molecular organization of plasma vWF appeared to have been altered by the presence of unusually large multimers, normally present only in the cellular compartments. Spontaneous platelet aggregation and hyperresponsiveness to ristocetin were also observed. All patients underwent therapeutic surgery. Within 1 month of the intervention, regardless of its efficacy as evaluated by the assay of plasma and urinary cortisol, an additional significant increase in levels of FVIII and vWF was observed, with a concomitant more pronounced representation of abnormally large vWF multimers in circulation. In the cured patients, a progressive decrease in the levels of FVIII and vWF was observed, beginning in the third month after surgery, with complete normalization of the pattern within 12 months of surgery; a concomitant improvement in the plasma vWF multimer pattern was also observed. In contrast, no significant changes in FVIII or vWF were found in patients with persistent Cushing's syndrome. Our findings emphasize that vWF abnormalities are also part of the prothrombotic state of Cushing's syndrome. Moreover, this study also identified a period of additional thrombotic risk immediately after surgery, as a result of the worsening of the hemostatic pattern.


Assuntos
Síndrome de Cushing/sangue , Fator VIII/metabolismo , Fator de von Willebrand/metabolismo , Adolescente , Adulto , Idoso , Síndrome de Cushing/urina , Dimerização , Feminino , Humanos , Hidrocortisona/sangue , Hidrocortisona/urina , Masculino , Pessoa de Meia-Idade , Fator de von Willebrand/química
8.
Blood Coagul Fibrinolysis ; 4(1): 177-81, 1993 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8457648

RESUMO

We report a family with a combined factor VII Padua defect and von Willebrand's disease (vWd). The propositus is a 9-year-old child with a moderate bleeding tendency who appeared to be heterozygous for both factor VII Padua and type I vWd. The diagnosis of factor VII Padua was based on a normal factor VII antigen and factor VII activity which was low with rabbit brain thromboplastin but normal with ox brain thromboplastin. Type I vWd was diagnosed because of a concomitant decrease of von Willebrand factor antigen (vWf:Ag) and vWf ristocetin-cofactor activity (vWf:RCoF), associated with the presence of vWf multimers of all sizes in plasma and platelets. The parents were not consanguineous but came from the same isolated river Piave valley in North Eastern Italy where the factor VII Padua defect was first described. The father had the factor VII Padua defect but was clinically asymptomatic in accordance with the heterozygous state. The propositus's mother had type I vWd and was mildly symptomatic. The propositus' sisters, who were clinically asymptomatic, were both heterozygotes for factor VII Padua. The infusion of DDAVP normalized the factor VIII/vWf pattern in all patients. In the propositus, in contrast to the mother and normal subjects, showed a more rapid clearance both of vWf and factor VIII. The same pattern, albeit to a lesser degree, was also observed in the father.


Assuntos
Deficiência do Fator VII/genética , Fator VII/genética , Tromboplastina/química , Doenças de von Willebrand/genética , Criança , Desamino Arginina Vasopressina/administração & dosagem , Deficiência do Fator VII/tratamento farmacológico , Feminino , Humanos , Itália , Masculino , Linhagem , Doenças de von Willebrand/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...